RecruitingNCT02422238
Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease
Disease Mechanisms and Markers for Non-alcoholic Steatohepatitis in a Population With Non-alcoholic Fatty Liver Disease: a Prospective Cohort Study With Biobank
Sponsor
Maastricht University Medical Center
Enrollment
500 participants
Start Date
Jun 1, 2015
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of the present prospective NAFLD cohort study (with biobank), of obese subjects with proven NAFLD based on liver biopsy and/or MRI, is to study factors contributing to the development of NASH in patients with simple steatosis and to identify and validate non-invasive markers for the diagnosis of NASH.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria3
- NAFLD diagnosis based on evidence of hepatic steatosis, either by imaging (using MRI) or by histology.
- BMI ≥ 30 kg/m2
- Between 18 - 65 years of age
Exclusion Criteria11
- Incompetent to understand and/or sign the informed consent.
- Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis
- Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female.
- Not able or willing to undergo MRI (for example claustrophobia, ICD, pacemaker).
- Not willing to be informed about unexpected findings by MRI
- Unwilling to collect bio samples.
- Pregnancy and breastfeeding.
- Indication or planned for bariatric surgery within one year after inclusion or a history of bariatric surgery.
- Diagnosis of liver cirrhosis and/or hepatocellular carcinoma.
- Current diagnosis of extrahepatic malignancy(s) or prior diagnosis within last 5 years.
- Individuals about to undergo or recovering from a surgical or otherwise medical procedure that will interfere with data collection and analyses planned within the current cohort, will initially be excluded from participation, but are offered the opportunity to participate at a later moment in time
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02422238
Related Trials
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss
NCT072377502 locations
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
NCT053309231 location
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
NCT071495711 location
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT070933463 locations
Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
NCT065645844 locations